Skip to content
Clinical Trials – home
Not yet recruiting

Effect of vicadrostat and empagliflozin on blood pressure in patients with uncontrolled hypertension

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on adults with uncontrolled hypertension, a condition where blood pressure remains high despite usual treatment. Participants will receive either the oral medication vicadrostat, the oral medication empagliflozin, or a matching placebo that looks the same but contains no active drug. Both drugs are taken as a film‑coated tablet once daily. Blood pressure is the force of blood against the walls of the arteries, and the systolic number is the higher value measured when the heart beats.

The aim of the trial is to see whether the combination of vicadrostat and empagliflozin can lower the office systolic blood pressure after 12 weeks compared with placebo. After a short screening period, participants will attend regular clinic visits where the study medication is given, blood pressure measurements are taken, and simple tests of vascular structure and function are performed to assess how the blood vessels are working. The study lasts for about three months, with visits scheduled at the start, during the treatment period, and at the end to collect the final results.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessment

    After joining the study, you will attend a baseline visit where your office systolic blood pressure and vascular health will be measured. These measurements provide the starting point for evaluating any changes during the trial.

  2. Step 2

    Randomization and Receipt of Study Medication

    Based on a random assignment, you will receive one of the following tablets:

    Empagliflozin – 10 mg film‑coated tablet taken orally once daily.

    Vicadrostat – tablet taken orally once daily as specified in the study protocol (exact dose not disclosed).

    Or a matching placebo tablet that looks identical to the active drug.

    The tablet you receive will be packaged in a way that keeps you and the study staff unaware of whether it contains the active drug or placebo.

  3. Step 3

    Daily Medication Intake for 12 Weeks

    You will take the assigned tablet every day, preferably at the same time each morning, with a glass of water.

    The medication must be taken for a total period of 12 weeks, unless you are asked to stop earlier by the study team for safety reasons.

  4. Step 4

    Week 12 Follow‑Up Visit

    At the end of the 12‑week treatment period, you will return for a follow‑up visit.

    During this visit, your office systolic blood pressure will be measured again to determine any change from the baseline value.

    The study medication will be discontinued after this final assessment.

Who can join the trial?

3 criteria

  • Be at least 18 years old but younger than 80 years at the time of screening.
  • Have uncontrolled arterial hypertension, which means your blood pressure is higher than normal when measured in the doctor’s office (average systolic pressure ≥ 140 mmHg or average diastolic pressure ≥ 90 mmHg) and also higher than normal on a 24‑hour monitoring device (average systolic ≥ 130 mmHg or diastolic ≥ 80 mmHg). Systolic is the top number that shows pressure when the heart beats; diastolic is the bottom number that shows pressure when the heart rests.
  • Be taking between one and three different blood‑pressure medicines (called antihypertensive drug classes) and have been on a stable dose of each medicine for at least four weeks before screening. One of these medicines must belong to the renin‑angiotensin system blockade group, which helps relax blood vessels and lower blood pressure.

Who cannot join the trial?

24 criteria

  • Having any known secondary cause of high blood pressure such as severe narrowing of the kidney arteries, untreated overactive or underactive thyroid, a tumor that makes excess adrenaline (pheochromocytoma), Cushing’s syndrome, excess aldosterone production, or a narrowed part of the aorta.
  • Having severe liver scarring (hepatic cirrhosis) classified as the most advanced stage (Child‑Pugh C).
  • Having liver enzyme tests (ALT or AST) that are more than three times higher than the normal upper limit.
  • Having had a stroke, a brief “mini‑stroke” (transient ischemic attack), unstable chest pain (unstable angina), or a heart attack within the past six months.
  • Being unable to follow the study rules or take the medication as required.
  • Being in an unstable health condition because of a serious illness that would interfere with the study.
  • Being pregnant, breastfeeding, or planning to become pregnant; women who could become pregnant must use a reliable form of birth control.
  • Having a blood potassium level of 5.2 mmol/L or higher (high potassium).
  • Having very poor kidney function (estimated glomerular filtration rate < 20 ml/min/1.73 m²) or a very high amount of protein in the urine (UACR ≥ 3500 mg/g).
  • Having consistently very high office blood pressure readings of 180/110 mmHg or higher.
  • Having taken medicines that block aldosterone effects (such as certain diuretics or renin inhibitors) or potassium‑sparing diuretics in the past 12 weeks.
  • Having moderate to severe heart failure (NYHA class III or IV).
  • Receiving systemic mineralocorticoid replacement therapy (for example, fludrocortisone).
  • Having known adrenal insufficiency (such as Addison disease).
  • Being allergic or unusually sensitive to the study drugs (vicadrostat, empagliflozin), other similar drugs, or any ingredients in the tablets (including lactose).
  • Having taken a combination of an ACE inhibitor and an ARB, or an ACE inhibitor/ARB with an ARNI, within the past 12 weeks.
  • Having a blood‑sugar control level (HbA1c) of 10 % or higher.
  • Planning to have major surgery during the study period.
  • Having taken part in another experimental drug or device study within the last 30 days or while any leftover study drug is still in the body.
  • Having a chronic problem with alcohol or drug abuse.
  • Having an active cancer or having been treated for cancer within the last two years, except for certain non‑melanoma skin cancers or very low‑grade cancers.
  • Having type 1 diabetes or other diabetes caused by the immune system.
  • Having used a SGLT2 inhibitor (a type of diabetes medicine) or insulin in the past three months.
  • Having a history of severe problems with blood pressure dropping when standing up (severe orthostatic dysregulation).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • BI 690517

    is an experimental oral tablet being tested to see if it can lower blood pressure and improve the health of blood vessels in people whose high blood pressure is not well controlled. In this study participants take the tablet once a day for twelve weeks, and researchers measure changes in their blood pressure and the way their blood vessels work.

  • Empagliflozin

    (commercially known as Jardiance) is a pill that is usually used to help control blood sugar in diabetes, but it also has effects that can lower blood pressure. In this trial the drug is given to participants with uncontrolled hypertension to find out whether it can reduce the pressure in the arteries and improve the structure and function of the blood vessels over a twelve‑week period.

What is already known about the treatment

  • BI 690517

    It is taken by mouth as a film‑coated tablet, 10 mg once daily. This compound is still experimental and has not been approved for any medical use. It is being studied for its ability to lower high blood pressure by helping blood vessels relax. It belongs to a class of investigational agents that target vascular tone.

  • Empagliflozin

    It is taken by mouth as a film‑coated tablet, 10 mg once daily. Empagliflozin is an approved medicine for type 2 diabetes and is also used to reduce heart‑related risks. It works by blocking a kidney protein that re‑absorbs sugar, causing extra glucose and water to be excreted, which can help lower blood pressure. It is classified as an SGL‑2 inhibitor, a type of oral glucose‑lowering drug.

Investigated diseases

Uncontrolled hypertension - This condition is defined by consistently high blood pressure that remains above the target level despite standard therapy. Over time the pressure can gradually increase, putting extra strain on the heart and blood vessels. The elevated pressure may lead to the thickening of arterial walls and reduced elasticity. As the condition persists, the body’s ability to regulate blood flow can become impaired. Without adequate control, the disease can progress from mild elevation to severe hypertension that is resistant to usual medications.
Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527729-36-00Protocol codeVANGUARDEstimated enrolment80 patientsSponsorUniversitaetsklinikum Erlangen AöR

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.